Evidence-based cardiovascular care in the community: A population-based cross-sectional study

BMC Family Practice

Volumn 5, Issue , 2004, Pages 1-23

  Putnam, Wayne ^a   Burge, Frederick I ^a   Lawson, Beverley ^a   Cox, Jafna L ^a   Sketris, Ingrid ^a   Flowerdew, Gordon ^a   Zitner, David ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; COMMUNITY CARE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; SEX DIFFERENCE; UNSTABLE ANGINA PECTORIS;

EID: 2642572801     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-5-6     Document Type: Article

References (37)

1. Canadian Cardiovascular Society: 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 1998, 14: 2C-23C.
2. Rochon PA, Anderson GM, Tu JV, Clark JP, Gurwitz JH, Szalai JP, Lau P: Use of β-blocker therapy in older patients after acute myocardial infarction in Ontario. Can Med Assoc J 1999, 161: 1403-1408.
3. Rochon PA, Anderson GM, Tu JV, Gurwitz JH, Clark JP, Shear NH, Lau P: Age- and gender-related use of low-dose drug therapy: The need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc 1999, 47: 954-959.
4. Rojas-Fernandez CH, Kephart GC, Sketris IS, Kass K: Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol 1999, 15: 291-296.
5. Khan N, Chockalingam A, Campbell NRC: Lack of control of high blood pressure and treatment recommendations in Canada. Can J Cardiol 2002, 18: 657-661.
6. Cox JL: Optimizing disease management at a health care system level: The improving Cardiovascular Outcomes in Nova Scotia (ICONS) Study. Can J Cardiol 1999, 15: 787-796.
7. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. Oslo, Norway, World Health Organization, 2001.
8. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345: 1667-1675.
9. Anand SS, Yusuf S: Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999, 282: 2058-2067.
10. SAS Institute Inc..SAS/STAT Version 8.2. Cary (NC), SAS Institute Inc, 1999.
11. Ko DT, Lee DS, Newman AM, Austin PC, Wang JT, Donovan LR, Tu JV: Improving trends in the use of evidence-based therapies in patients with acute myocardial infarction. Can J Cardiol 2003, 19: 159A.
12. Pilote L, Beck CA, Karp I, Alter D, Austin P, Cox J, Humphries K, Jackevicius C, Richard H, Tu JV: Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 2004, 20: 61-67.
13. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV: The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. Can Med Assoc J 2003, 168: 553-557.
14. Klungel OH, Heckbert SR, de Boer A, Leufkens HGM, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM: Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002, 36: 751-757.
15. Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM: Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: A population-based perspective. Arch Intern Med 2001, 161: 1521-1528.
16. Mamdani MM, Tu JV: Did the major clinical trials of statins affect prescribing behaviour? Can Med Assoc J 2001, 164: 1695-1696.
17. Jackevicius CA, Anderson GM, Leiter L, Tu JV: Use of the statins in patients after acute myocardial infarction: Does evidence change practice? Arch Intern Med 2001, 161: 183-188.
18. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, Laragh JH, McInnes G, Schork AM, Smith B et al.: VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003, 16: 544-548.
19. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Heller G, Keil U: Factors associated with differences in antihypertensive drug treatment: results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95. Soz Praventivmed 2002, 47: 128-142.
20. Steyn K, Gaziano TA, Bradshaw D, Laubscher R, Fourie J: Hypertension in South African adults: Results from the Demographic and Health Survey, 1998. J Hypertens 2001, 19: 1717-1725.
21. Sudano JJ, Baker DW: Antihypertensive medication use in hispanic adults: A comparison with black adults and white adults. Med Care 2001, 39: 575-587.
22. Fagard RH, Van den Enden M, Leeman M, Warling X: Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002, 20: 1297-1302.
23. Krumholz HM, Radford MJ, Want Y, Chen J, Heiat A, Marciniak TA: National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998, 280: 623-629.
24. Fuat A, Hungin APS, Murphy JJ: Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003, 326: 196.
25. Putnam W, Twohig P, Burge F, Jackson L, Cox J: A qualitative study of evidence in primary care: What the practitioners are saying. Can Med Assoc J 2002, 166: 1525-1530.
26. Allen CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR, Li Q, Anderson JL: Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002, 40: 1777-1785.
27. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, McLaughlin B, Morris N, Cheng SC, Hauptman PJ et al.: Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: Evidence for undertreatment in women and the elderly. Arch Intern Med 1996, 156: 799-805.
28. Ganz DA, Lamas GA, Orav EJ, Goldman L, Gutierrez PR, Mangione CM: Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. J Am Geriatr Soc 1999, 47: 145-150.
29. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, Kromhout D, Lindemans AD, Avorn J, Porsius AJ, de Boer A: Undertreatment of hypercholesterolaemia: A population-based study. J Clin Pharmacol 2003, 55: 389-397.
30. Pears E, Hannaford PC, Taylor MW: Gender, age and deprivation differences in the primary care management of hypertension in Scotland: A cross-sectional database study. Fam Pract 2003, 20: 22-31.
31. Dombrook-Lavender KA, Roth MT, Pieper JA: Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother 2003, 37: 1867-1876.
32. Ayanian JZ, Landrum MB, McNeil BJ: Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med 2002, 162: 1013-1019.
33. Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288: 462-467.
34. Di Cecco R., Patel U., and Upshur R. E. G.Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice? BMC Family Practice 2002 3(1).
35. Weiss R, Buckley K, Clifford T: Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000. Clin Ther 2002, 24: 1451-1462.
36. Cox JL, Zitner D, Courtney KD, MacDonald DL, Paterson G, Cochrane B, Mathers J, Henry H, Flowerdew G, Johnstone DE: Undocumented patient information: An impediment to quality of care. Am J Med 2003, 114: 211-216.
37. Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342: 145-153.